Source: Sharecast
The European Commission was expected to deliver its final decision in February 2026 and, if approved, the expanded indication will make Arexvy available to the wider adult population.
Arexvy was the first RSV vaccine cleared in Europe for the prevention of lower respiratory tract disease in adults aged 60 and above, as well as those aged 50–59 considered at increased risk.
Sanjay Gurunathan, GSK's head of vaccines and infectious diseases research and development unit, said: "Today's positive CHMP opinion is an important step towards bringing more options to prevent severe RSV disease for adults in Europe. GSK is dedicated to increasing access to our vaccines in broader adult populations and we continue to drive innovation to help make it easier for healthcare professionals to offer protection against severe RSV disease."
As of 0820 GMT, GSK shares were up 0.14% at 1,823.50p.
Reporting by Iain Gilbert at Sharecast.com